tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2024 Nov;18(11):e70014.
doi: 10.1111/irv.70014. Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK
Joanna Waldock[SUP] 1 [/SUP], Rebecca J Cox[SUP] 2 [/SUP], Christopher Chiu[SUP] 3 [/SUP], Kanta Subbarao[SUP] 4 [/SUP], Adrian Wildfire[SUP] 5 [/SUP], Wendy Barclay[SUP] 3 [/SUP], Puck B van Kasteren[SUP] 6 [/SUP], John McCauley[SUP] 7 [/SUP], Colin A Russell[SUP] 8 [/SUP], Derek Smith[SUP] 9 [/SUP], Ryan S Thwaites[SUP] 10 [/SUP], John S Tregoning[SUP] 3 [/SUP], Othmar G Engelhardt[SUP] 1 [/SUP]
Affiliations
Controlled human infection models (CHIMs) are a critical tool for the understanding of infectious disease progression, characterising immune responses to infection and rapid assessment of vaccines or drug treatments. There is increasing interest in using CHIMs for vaccine development and an obvious need for widely available and fit-for-purpose challenge agents. Inno4Vac is a large European consortium working towards accelerating and de-risking the development of new vaccines, including the development of CHIMs for influenza, respiratory syncytial virus and Clostridioides difficile. This report (in two parts) summarises a workshop held at the MHRA in 2021, focused on how to select CHIM candidate strains of influenza and respiratory syncytial virus (RSV) based on desirable virus characteristics and which immune assays would provide relevant information for assessing pre-existing and post-infection immune responses and defining correlates of protection. This manuscript (Part 1) summarises presentations and discussions centred around influenza CHIMs and immune assays (a second manuscript summarises RSV CHIM and immune assays: Inno4Vac workshop report Part 2: RSV CHIM strain selection and immune assays for RSV CHIM studies, November 2021, MHRA, UK).
Keywords: controlled human infection model (CHIM); controlled human influenza virus infection model (CHIVIM); correlates of protection; immune assays; influenza viruses.
. 2024 Nov;18(11):e70014.
doi: 10.1111/irv.70014. Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK
Joanna Waldock[SUP] 1 [/SUP], Rebecca J Cox[SUP] 2 [/SUP], Christopher Chiu[SUP] 3 [/SUP], Kanta Subbarao[SUP] 4 [/SUP], Adrian Wildfire[SUP] 5 [/SUP], Wendy Barclay[SUP] 3 [/SUP], Puck B van Kasteren[SUP] 6 [/SUP], John McCauley[SUP] 7 [/SUP], Colin A Russell[SUP] 8 [/SUP], Derek Smith[SUP] 9 [/SUP], Ryan S Thwaites[SUP] 10 [/SUP], John S Tregoning[SUP] 3 [/SUP], Othmar G Engelhardt[SUP] 1 [/SUP]
Affiliations
- PMID: 39496425
- DOI: 10.1111/irv.70014
Controlled human infection models (CHIMs) are a critical tool for the understanding of infectious disease progression, characterising immune responses to infection and rapid assessment of vaccines or drug treatments. There is increasing interest in using CHIMs for vaccine development and an obvious need for widely available and fit-for-purpose challenge agents. Inno4Vac is a large European consortium working towards accelerating and de-risking the development of new vaccines, including the development of CHIMs for influenza, respiratory syncytial virus and Clostridioides difficile. This report (in two parts) summarises a workshop held at the MHRA in 2021, focused on how to select CHIM candidate strains of influenza and respiratory syncytial virus (RSV) based on desirable virus characteristics and which immune assays would provide relevant information for assessing pre-existing and post-infection immune responses and defining correlates of protection. This manuscript (Part 1) summarises presentations and discussions centred around influenza CHIMs and immune assays (a second manuscript summarises RSV CHIM and immune assays: Inno4Vac workshop report Part 2: RSV CHIM strain selection and immune assays for RSV CHIM studies, November 2021, MHRA, UK).
Keywords: controlled human infection model (CHIM); controlled human influenza virus infection model (CHIVIM); correlates of protection; immune assays; influenza viruses.